| ORIGINAL ARTICLE |
|
| Year : 2016 | Volume
: 12
| Issue : 1 | Page : 254-258 |
|
|
Serum carcinoembryonic antigen levels predicts the efficacy of EGFR-TKI in non-small cell lung cancer harboring EGFR mutations
Zhang Yanwei, Jin Bo, Lou Yuqing, Li Rong, Zhang Xueyan, Hu Song, Han Baohui
Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, People's Republic China
Correspondence Address:
Han Baohui
Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, 241 West Huai Hai Road, Shanghai
People's Republic China
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0973-1482.153666
|
|
|
Objectives: Not all the patients harboring epidermal growth factor receptor (EGFR) mutations have a clinical response after the treatment of EGFR-tyrosine kinase inhibitor (TKI). The purpose of the present study was to find whether the baseline carcinoembryonic antigen (CEA) levels were associated with the efficacy of EGFR-TKI in patients harboring EGFR mutations.
Materials and Methods: Clinical features, serum tumor marker levels, and survival time were analyzed, retrospectively, in 200 non-small cell lung cancer (NSCLC) patients harboring EGFR mutations treated with EGFR-TKI.
Results: The total objective response rate (ORR) is 44.0% and disease control rate is 84.5%. The disease control rate in the patients with high CEA levels was significantly higher than that with low CEA levels (88.3 vs 74.5%, P = 0.029). There was no significant difference in progression-free survival (PFS) between high (≥5 ng/ml) and normal CEA groups (< ng/ml; 12.0 vs 8.3m, and P = 0.055). The PFS in patients with higher CEA levels (≥ 20 ng/ml) was longer than in patients with lower CEA levels (< ng/ml; 12.8 vs 8.7m, P = 0.016). Multivariate analysis shows that high CEA level (> ng/ml) were independent predictive factors for PFS (HR = 1.412, 93% CI: 1.042–1.913, P = 0.026).
Conclusions: Baseline serum CEA levels can serve as predictive factors for the treatment of EGFR-TKI in NSCLC patients harboring EGFR mutations. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
